1887

Abstract

Latent membrane protein 2A (LMP2A) of Epstein–Barr virus (EBV) provides developmental and survival signals that mimic those of a B-cell receptor (BCR). Expression of LMP2A during B-cell development results in the ability of B cells to exit the bone marrow in the absence of a BCR and persist in the periphery, where they would normally undergo apoptosis. This study extends the current knowledge of LMP2A function by examining the growth properties of bone marrow B cells from TgE LMP2A mice. Despite the lack of pre-BCR expression, bone marrow B cells from TgE LMP2A mice proliferate and survive in low concentrations of interleukin 7, similar to wild-type cells. Constitutive phosphorylation of ERK/MAPK and PI3K/Akt in TgE LMP2A bone marrow B cells is also reminiscent of signalling through the pre-BCR, altogether demonstrating that LMP2A provides a pre-BCR-like signal to developing B cells.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.2008/001461-0
2008-07-01
2021-10-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/7/1563.html?itemId=/content/journal/jgv/10.1099/vir.0.2008/001461-0&mimeType=html&fmt=ahah

References

  1. Bannish G., Fuentes-Panana E. M., Cambier J. C., Pear W. S., Monroe J. G. 2001; Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med 194:1583–1596 [CrossRef]
    [Google Scholar]
  2. Bell A. I., Groves K., Kelly G. L., Croom-Carter D., Hui E., Chan A. T., Rickinson A. B. 2006; Analysis of Epstein–Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 87:2885–2890 [CrossRef]
    [Google Scholar]
  3. Burkhardt A. L., Bolen J. B., Kieff E., Longnecker R. 1992; An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol 66:5161–5167
    [Google Scholar]
  4. Caldwell R. G., Wilson J. B., Anderson S. J., Longnecker R. 1998; Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405–411 [CrossRef]
    [Google Scholar]
  5. Caldwell R. G., Brown R. C., Longnecker R. 2000; Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74:1101–1113 [CrossRef]
    [Google Scholar]
  6. Chen S. Y., Lu J., Shih Y. C., Tsai C. H. 2002; Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol 76:9556–9561 [CrossRef]
    [Google Scholar]
  7. Corcoran A. E., Smart F. M., Cowling R. J., Crompton T., Owen M. J., Venkitaraman A. R. 1996; The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. EMBO J 15:1924–1932
    [Google Scholar]
  8. Corfe S. A., Gray A. P., Paige C. J. 2007; Generation and characterization of stromal cell independent IL-7 dependent B cell lines. J Immunol Methods 325:9–19 [CrossRef]
    [Google Scholar]
  9. Era T., Ogawa M., Nishikawa S., Okamoto M., Honjo T., Akagi K., Miyazaki J., Yamamura K. 1991; Differentiation of growth signal requirement of B lymphocyte precursor is directed by expression of immunoglobulin. EMBO J 10:337–342
    [Google Scholar]
  10. Fang W., Mueller D. L., Pennell C. A., Rivard J. J., Li Y. S., Hardy R. R., Schlissel M. S., Behrens T. W. 1996; Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity 4:291–299 [CrossRef]
    [Google Scholar]
  11. Fleming H. E., Paige C. J. 2001; Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B cell transition via an ERK/MAP kinase-dependent pathway. Immunity 15:521–531 [CrossRef]
    [Google Scholar]
  12. Fleming H. E., Paige C. J. 2002; Cooperation between IL-7 and the pre-B cell receptor: a key to B cell selection. Semin Immunol 14:423–430 [CrossRef]
    [Google Scholar]
  13. Fruehling S., Longnecker R. 1997; The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235:241–251 [CrossRef]
    [Google Scholar]
  14. Fruehling S., Lee S. K., Herrold R., Frech B., Laux G., Kremmer E., Grasser F. A., Longnecker R. 1996; Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70:6216–6226
    [Google Scholar]
  15. Fruehling S., Swart R., Dolwick K. M., Kremmer E., Longnecker R. 1998; Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol 72:7796–7806
    [Google Scholar]
  16. Fuentes-Panana E. M., Bannish G., Shah N., Monroe J. G. 2004; Basal Ig α /Ig β signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol 173:1000–1011 [CrossRef]
    [Google Scholar]
  17. Fukuda M., Longnecker R. 2005; Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol 79:8655–8660 [CrossRef]
    [Google Scholar]
  18. Hardy R. R., Carmack C. E., Shinton S. A., Kemp J. D., Hayakawa K. 1991; Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 173:1213–1225 [CrossRef]
    [Google Scholar]
  19. Ikeda M., Longnecker R. 2005; Pre-B-cell colony formation assay. Methods Mol Biol 292:279–284
    [Google Scholar]
  20. Jacob A., Cooney D., Pradhan M., Coggeshall K. M. 2002; Convergence of signaling pathways on the activation of ERK in B cells. J Biol Chem 277:23420–23426 [CrossRef]
    [Google Scholar]
  21. Kieff E. D., Rickinson A. B. 2007; Epstein-Barr virus and its replication. In Fields Virology , 5th edn. pp 2603–2654Edited by David P. M. H., Knipe M., Griffin D. E., Lamb R. A., Martin M. A., Roizman B., Straus S. E. Philadelphia, PA: Lippincott-Raven Publishers;
    [Google Scholar]
  22. Konishi K., Maruo S., Kato H., Takada K. 2001; Role of Epstein–Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J Gen Virol 82:1451–1456
    [Google Scholar]
  23. Longnecker R. 2000; Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?. Adv Cancer Res 79:175–200
    [Google Scholar]
  24. Longnecker R., Druker B., Roberts T. M., Kieff E. 1991; An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65:3681–3692
    [Google Scholar]
  25. Lu J., Lin W. H., Chen S. Y., Longnecker R., Tsai S. C., Chen C. L., Tsai C. H. 2006; Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 281:8806–8814 [CrossRef]
    [Google Scholar]
  26. Mancao C., Hammerschmidt W. 2007; Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110:3715–3721 [CrossRef]
    [Google Scholar]
  27. Marshall A. J., Fleming H. E., Wu G. E., Paige C. J. 1998; Modulation of the IL-7 dose-response threshold during pro-B cell differentiation is dependent on pre-B cell receptor expression. J Immunol 161:6038–6045
    [Google Scholar]
  28. Miller C. L., Longnecker R., Kieff E. 1993; Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol 67:3087–3094
    [Google Scholar]
  29. Miller C. L., Lee J. H., Kieff E., Longnecker R. 1994; An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91:772–776 [CrossRef]
    [Google Scholar]
  30. Miller C. L., Burkhardt A. L., Lee J. H., Stealey B., Longnecker R., Bolen J. B., Kieff E. 1995; Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155–166 [CrossRef]
    [Google Scholar]
  31. Monroe J. G. 2006; ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 6:283–294 [CrossRef]
    [Google Scholar]
  32. Morrison J. A., Klingelhutz A. J., Raab-Traub N. 2003; Epstein-Barr virus latent membrane protein 2A activates β -catenin signaling in epithelial cells. J Virol 77:12276–12284 [CrossRef]
    [Google Scholar]
  33. Panousis C. G., Rowe D. T. 1997; Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase. J Virol 71:4752–4760
    [Google Scholar]
  34. Portis T., Longnecker R. 2004; Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23:8619–8628 [CrossRef]
    [Google Scholar]
  35. Portis T., Dyck P., Longnecker R. 2003; Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102:4166–4178 [CrossRef]
    [Google Scholar]
  36. Rechsteiner M. P., Berger C., Weber M., Sigrist J. A., Nadal D., Bernasconi M. 2007; Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein–Barr virus in Burkitt's lymphoma Akata cells. J Gen Virol 88:1454–1459 [CrossRef]
    [Google Scholar]
  37. Rickinson A. B., Kieff E. 2007; Epstein-Barr virus. In Fields Virology , 5th edn. pp 2655–2700Edited by David P. M. H., Knipe M., Griffin D. E., Lamb R. A., Martin M. A., Roizman B., Straus S. E. Philadelphia, PA: Lippincott-Raven Publishers;
    [Google Scholar]
  38. Scholle F., Bendt K. M., Raab-Traub N. 2000; Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74:10681–10689 [CrossRef]
    [Google Scholar]
  39. Shaffer A. L., Schlissel M. S. 1997; A truncated heavy chain protein relieves the requirement for surrogate light chains in early B cell development. J Immunol 159:1265–1275
    [Google Scholar]
  40. Steelman L. S., Pohnert S. C., Shelton J. G., Franklin R. A., Bertrand F. E., McCubrey J. A. 2004; JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189–218 [CrossRef]
    [Google Scholar]
  41. Swanson-Mungerson M. A., Caldwell R. G., Bultema R., Longnecker R. 2005; Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J Virol 79:7355–7362 [CrossRef]
    [Google Scholar]
  42. Swanson-Mungerson M., Bultema R., Longnecker R. 2006; Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro . J Virol 80:6764–6770 [CrossRef]
    [Google Scholar]
  43. Tao Q., Robertson K. D., Manns A., Hildesheim A., Ambinder R. F. 1998; Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 91:1373–1381
    [Google Scholar]
  44. Teh Y. M., Neuberger M. S. 1997; The immunoglobulin (Ig) α and Ig β cytoplasmic domains are independently sufficient to signal B cell maturation and activation in transgenic mice. J Exp Med 185:1753–1758 [CrossRef]
    [Google Scholar]
  45. Thorley-Lawson D. A. 2005; EBV the prototypical human tumor virus–just how bad is it?. J Allergy Clin Immunol 116:251–261 [CrossRef]
    [Google Scholar]
  46. Thorley-Lawson D. A., Gross A. 2004; Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328–1337 [CrossRef]
    [Google Scholar]
  47. Xue S. A., Labrecque L. G., Lu Q. L., Ong S. K., Lampert I. A., Kazembe P., Molyneux E., Broadhead R. L., Borgstein E., Griffin B. E. 2002; Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 99:635–643 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.2008/001461-0
Loading
/content/journal/jgv/10.1099/vir.0.2008/001461-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error